Effect of lisinopril therapy on serum leptin, oxidative stress and C-reactive protein in hypertensive patients

Zeina A. Althanoon¹, Isam H. Mahmood²

¹ College of Pharmacy, University of Mosul, Mosul, Iraq
² Department of Pharmacy, College Al-Noor University, Bartella, Iraq

Corresponding author: Zeina A. Althanoon (ph.zeinaalthanoon@yahoo.com)

Received 17 August 2021 • Accepted 30 August 2021 • Published 10 September 2021

Abstract

The pathogenesis of essential hypertension through the interaction with elements of the rennin angiotensin aldosterone system is affected by oxidative stress and inflammation. The present study aimed to assess the effects of ACE-Inhibitor, lisinopril, on blood pressure, lipid profiles (total cholesterol, triglycerides, LDL and HDL), MDA, and TAS, hsCRP, and serum leptin levels in hypertensive patients. A case control study included 100 newly diagnosed mild to moderate hypertensive patients and another 100 apparently healthy aged and sex matched subjects as controls. The patients were treated with 10 mg lisinopril orally per day for three months' duration. Venous blood sample was taken to test levels of MDA, GSH and TAS, hsCRP, lipid profiles and leptin in the serum before and after lisinopril therapy for both patients and controls. Systolic and diastolic blood pressure were also assessed before and after lisinopril therapy for both patients and controls. In hypertensive patients treated with lisinopril, markers of oxidative stress (MDA, TAS and GSH), high sensitive C-reactive protein and leptin were all found to be decreased significantly after drug treatment (p < 0.01). Lisinopril affectively lowered systolic and diastolic BP values (p < 0.01). A significant decrease in lipid profile (p < 0.01) with a significant increase in HDL-C and TAS levels (p < 0.01) were found in lisinopril treated group in comparison with their values before treatment. Lisinopril may be used as a treatment for high blood pressure, as well as for the insulin resistance, hyperleptinemic, and low-grade inflammatory states that are associated with the disease.

Keywords

Lisinopril, Oxidative stress, C-reactive protein, Leptin, Hypertension

Introduction

Hypertension is a chronic clinical condition in which the blood pressure gradually increases (Merkhan et al. 2021). A systolic blood pressure of less than 140 mmHg and a diastolic blood pressure of less than 90 mmHg are indicative of controlled hypertension (Ames et al. 2019; Arif et al. 2019). Although it is typically asymptomatic, it can have a long-term detrimental effect on the renal, cardiopulmonary, and neurovascular systems. Hypertension is classified into two types: essential hypertension and secondary hypertension (Balakumar et al. 2019). The two types of hypertension are essential hypertension and secondary hypertension. Essential hypertension is more prevalent than secondary hypertension, which affects 90–95% of people and is caused by a combination of genetic and environmental factors. Secondary hypertension affects between 5% and 10% of hypertensive patients and is caused
by a variety of observable and treatable factors, such as deteriorating kidney function (Chandra et al. 2014; Bottini et al. 2019; Faulkner and Belin de Chantemelle 2012).

When combined with chronic sympathetic nervous system activation, particularly of the kidney, leptin has been shown to influence nitric oxide production and natriuresis, which has been linked to sodium retention, systemic vasconstriction, and blood pressure elevation (Shankar and Xiao 2010; Serafi et al. 2016; Ahmad et al. 2021). As a consequence, direct correlation has been established between elevated leptin levels and the development of hypertension in obese people (Almukhtar et al. 2021; Younis et al. 2021). There have been few studies comparing leptin levels prior to and following antihypertensive therapy, as well as their tumor necrosis factor levels and the production of reactive oxygen species (Xie and Bollag 2016; Von Schnurbein et al. 2019).

The renin angiotensin aldosterone system (RAAS) and reactive oxygen species (ROS) have been extensively studied (Romero and Reckelhoff 1999). Angiotensin II, a vasoconstrictor mediator, generates reactive oxygen species (ROS) and is a strong inducer of oxidative stress (Mahmood et al. 2012).

Angiotensin II stimulates the expression and function of Nicotine Amide Adenine Dinucleotide Phosphate (NADPH) oxidase in vascular wall and coronary microvascular endothelial cells, as well as the production of superoxide (Dimitriadis et al. 2016; Dikalova et al. 2020). Additionally, angiotensin II’s long-term effects may result in reduced expression of anti-oxidant defense mechanisms such as superoxide dismutase. Additionally, an increase in ROS intern may promote the expression of RAAS components necessary for angiotensin II formation (Abdulrazzaq et al. 2020; Faisal et al. 2020). The inhibitors of the angiotensin converting enzyme and the angiotensin II receptor were found to have significant antioxidant properties that outperformed vitamin E and other commonly used antioxidants (Al-Hamodi et al. 2014; Merkhan and Abdullah 2020).

The aim of this study was to determine the effect of lisinopril on serum leptin, lipid profile (TC, TG, LDL, and HDL), malondialdehyde (MDA), total antioxidant status (TAS), glutathione (GSH), and high sensitivity C-reactive protein (hsCRP) in newly diagnosed hypertensive patients.

**Material and methods**

A total of 200 subjects were recruited and completed the study. The patient group includes one hundred newly-diagnosed hypertensive patients collected with the assistance of the medical staff of the out-patient clinic at IBN-SINA teaching hospital. The remaining 100 subjects were the control group of apparently healthy volunteers ranging in age from 28 to 65 years with a mean of 37.86 ± 10.02 years. The study was an open, controlled, comparative clinical trial conducted to evaluate the effect of lisinopril therapy on blood pressure, oxidative stress markers (MDA, GSH and TAS), lipid profile, inflammatory marker (hs-CRP) and serum leptin levels. Blood pressure was measured at before and after drug administration using a standard mercury sphygmanometer (Frese et al. 2011). The target blood pressure was less than 140/90 mmHg following treatment.

Antihypertensive efficacy was determined by comparing blood pressure levels before and after drug therapy and by determining the proportion of patients who achieved normal blood pressure following therapy. Before and after two months of therapy, approximately 10 ml of venous blood was drawn from patients using disposable plastic syringes. The sera were separated and stored at (-20 °C) until further analysis following centrifugation of the blood (27). They were recruited as controls to establish normal values for SBP, DBP, MDA, TAS, hs-CRP, lipid profile, and serum leptin. Serum MDA levels were determined using a thiobarbituric acid (TBA) assay, and TAS and GSH levels were determined using the Randox TAS Kit.

High sensitivity C-reactive protein, hs-CRP was quantified in human sera using an enzyme-linked immunosorbent assay (ELISA). A Biochek hs-CRP ELISA kit was used. The level of serum leptin was determined using the IBL leptin ELISA kit (Germany). The serum lipid profile was determined enzymatically using a kit supplied by BIOLABO (France). Body mass index (BMI) was calculated using the following equation: (Kg) / (m2). Standard chemical methods were used to determine the lipid profile (TG, TC, LDL-C and HDL-C). The study’s mean and standard deviation were calculated statistically (SD). For statistical comparisons, ANOVA and paired t-tests were used. 0.05 was chosen as the level of statistical significance. Frequency tables were analyzed using the chi-square test, while mean and standard deviation tables were analyzed using the independent sample t-test. The Pearson correlation coefficient is used to determine the relationship between the markers under investigation.

**Results**

The baseline characteristics of the data were shown in Table 1. Body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), malondialdehyde (MDA) and Total antioxidant status (TAS), lipid profile and following antihypertensive therapy, as well as their tumor necrosis factor levels and the production of reactive oxygen species (Xie and Bollag 2016; Von Schnurbein et al. 2019).

**Table 1.** Comparison between control and lisinopril group for the studied parameters.

| Parameter | Control (n = 100) | Means±SD | Before treatment (n = 100) | P-value |
|-----------|------------------|----------|---------------------------|---------|
| Weight (Kg) | 74.60 ± 11.5 | 85.65 ± 8.79 | <0.001 |
| BMI (Kg/m2) | 27.20 ± 2.8 | 30.46 ± 1.38 | <0.001 |
| SBP (mmHg) | 127.05 ± 6.93 | 143.60 ± 7.72 | <0.001 |
| DBP (mmHg) | 79.24 ± 4.91 | 92.18 ± 6.21 | <0.001 |
| TC (mmol/l) | 5.45 ± 1.65 | 4.40 ± 1.93 | <0.001 |
| TG (mmol/l) | 1.48 ± 1.55 | 2.63 ± 1.6 | <0.001 |
| HDL (mmol/l) | 2.60 ± 1.28 | 1.90 ± 1.30 | <0.001 |
| LDL (mmol/l) | 1.48 ± 1.60 | 2.26 ± 1.65 | <0.001 |
| hsCRP mg/L | 5.60 ± 0.17 | 12.12 ± 9.81 | <0.001 |
| MDA (nmol/ml) | 4.26 ± 0.78 | 10.05 ± 3.16 | <0.001 |
| TAS (mmol/l) | 1.55 ± 0.22 | 1.53 ± 0.26 | <0.001 |
| GSH (µg/ml) | 3.46 ± 1.37 | 2.37 ± 0.84 | <0.001 |
| Leptin (ng/ml) | 12.34 ± 0.22 | 17.08 ± 8.16 | <0.001 |

Using the unpaired t-test, there is a significant difference at p ≤ 0.001.
Total cholesterol (TC), Triglycerides (TG), Low density lipoprotein cholesterol (LDL), High density lipoprotein cholesterol (HDL), high sensitivity C-reactive protein (hsCRP) and leptin levels were significantly increased in patients with hypertension compared to the healthy subjects group (p < 0.01), while high density lipoprotein cholesterol (HDL) and the antioxidant glutathione (GSH) levels were significantly lower (p < 0.01) in these patients as shown in Table 1. On the other hand, comparison of baseline and after treatment with the antihypertensive drug lisinopril, the levels of BMI, SBP, DBP, MDA, lipid profile, hs-CRP and leptin levels in hypertensive patients were significantly decreased and HDL, TAS and GSH levels were significantly increased in comparison with pretreatment values as shown in Table 2.

Concerning for correlations study, the results found that there was a positive correlation between leptin and hsCRP, MDA, TC, TG and LDL while there was a negative correlation between leptin and TAS, GSH and HDL as shown in Table 3. A significant positive correlation was found between systolic and diastolic blood pressure and leptin in all studied groups (p < 0.01). Table 4. The difference in mean MDA, hsCRP, TAS and GSH levels among the study sampled groups were shown in Figure 1.

**Table 1.** Comparison of studied parameters before and after lisinopril therapy.

| Parameter  | Before treatment | After treatment | P value |
|------------|-----------------|----------------|---------|
| Weight (Kg) | 85.65 ± 8.79    | 81.46 ± 7.61   | <0.001  |
| BMI (Kg/m2) | 30.46 ± 1.38    | 30.95 ± 1.8    | <0.001  |
| SBP (mmHg)  | 143.60 ± 7.72   | 128.90 ± 7.14  | <0.001  |
| DBP (mmHg)  | 92.18 ± 6.21    | 80.45 ± 5.84   | <0.001  |
| TC (mmol/L) | 4.40 ± 1.93     | 3.35 ± 1.00    | <0.001  |
| TG (mmol/L) | 2.63 ± 1.6      | 1.48 ± 1.03    | <0.001  |
| HDL (mmol/L)| 1.90 ± 1.30     | 2.46 ± 1.43    | <0.001  |
| LDL (mmol/L)| 2.26 ± 1.65     | 1.89 ± 1.52    | <0.001  |
| hsCRP (mg/L)| 12.12 ± 9.81    | 7.2 ± 8.9      | <0.001  |
| MDA (nmol/ml)| 10.05 ± 3.16   | 8.34 ± 2.32    | <0.001  |
| TAS (mmol/l)| 1.53 ± 0.26     | 1.94 ± 0.17    | <0.001  |
| GSH (µg/ml) | 2.37 ± 0.84     | 4.89 ± 0.77    | <0.001  |

Significant difference at p < 0.001 using unpaired t-test.

**Figure 1.** The difference in mean of measured parameters (MDA, hsCRP, TAS, and GSH) among the study sampled groups.

**Table 2.** Comparison of studied parameters before and after lisinopril therapy.

| Parameter  | Before treatment | After treatment | P value |
|------------|-----------------|----------------|---------|
| Weight (Kg) | 85.65 ± 8.79    | 81.46 ± 7.61   | <0.001  |
| BMI (Kg/m2) | 30.46 ± 1.38    | 30.95 ± 1.8    | <0.001  |
| SBP (mmHg)  | 143.60 ± 7.72   | 128.90 ± 7.14  | <0.001  |
| DBP (mmHg)  | 92.18 ± 6.21    | 80.45 ± 5.84   | <0.001  |
| TC (mmol/L) | 4.40 ± 1.93     | 3.35 ± 1.00    | <0.001  |
| TG (mmol/L) | 2.63 ± 1.6      | 1.48 ± 1.03    | <0.001  |
| HDL (mmol/L)| 1.90 ± 1.30     | 2.46 ± 1.43    | <0.001  |
| LDL (mmol/L)| 2.26 ± 1.65     | 1.89 ± 1.52    | <0.001  |
| hsCRP (mg/L)| 12.12 ± 9.81    | 7.2 ± 8.9      | <0.001  |
| MDA (nmol/ml)| 10.05 ± 3.16   | 8.34 ± 2.32    | <0.001  |
| TAS (mmol/l)| 1.53 ± 0.26     | 1.94 ± 0.17    | <0.001  |
| GSH (µg/ml) | 2.37 ± 0.84     | 4.89 ± 0.77    | <0.001  |
| Leptin (ng/ml)| 17.08 ± 8.16 | 14.97 ± 8.93  | <0.001  |

**Table 3.** Correlation matrix between different parameters in the studied group.

| Parameter | Correl coeff* |
|-----------|----------------|
| Leptin    |                |
| Age       | R: 0.241       |
| WT        | 0.813          |
| hsCRP     | 0.238          |
| MDA       | 0.692          |
| TAS       | 0.287          |
| GSH       | -0.734         |
| TC        | R: -0.546      |
| HDL       | -0.734         |
| LDL       | -0.734         |
| TG        | -0.579         |
| TC        | -0.526         |
| HDL       | -0.561         |
| LDL       | -0.745         |
| TG        | -0.579         |

* Pearson correlation method (r) was used.
In addition, leptin may contribute to the regulation of blood pressure in hypertensive normal as well as in the obese patient (Furuhashi et al. 2003). Numerous clinical findings corroborate the existence of a link between interleukin-6, IL-6, and CRP (Volpe 2008).

Additional studies have provided data that contradicting previous reports about leptin levels in high blood pressure states have been performed (Herold et al. 2020). Elevated levels of leptin levels have been observed in some previous studies in patients with high blood pressure (Hage 2014). Research has also shown that plasma levels of leptin were lower with treatment of hypertension and higher in those patients who experience resolution of their hypertension (De Faria et al. 2013). As indicated by this study’s findings, Lisinopril treatment resulted in significant reduction in serum MDA, hs-CRP, and leptin levels, as well as a substantial increase in TAS and GSH in patients with hypertension in agreement with these findings, our current studies, in individuals found that patients suffering from hypertension could not produce enough antioxidants to combat the oxidative stress, but antioxidant treatment along with antihypertensive drugs appears to help with rapid relief. As compared to normotensive patients, the levels of MDA, hs-CRP, and leptin were reduced in those taking lisinopril, while those of TAS and GSH levels were elevated. This effect may be mediated by inhibition in improving T cell immune functions (Kamimura et al. 2018) which other studies have shown to be capable of preserving the cell membranes from oxidation as well as substantiating the claim that they can protect the lipid membrane from attack by ROS (Nowzari et al. 2018). One study discovered a link between adiponectin expression and body fat mass (Luo et al. 2005). They concluded that, while ACEIs are well known for their antioxidant properties, they may also affect adipocytokine levels (Katsiki et al. 2011) via non-antioxidant mechanisms such as inhibition of protein kinase C and regulation of cell growth and expression of the membrane glycoprotein CD36 (Fontana et al. 2014).

### Discussion

Angiotensin-converting enzyme (ACE) inhibitors have been shown to improve endothelial function and oxidative stress, as well as inflammatory factors (Abdollahi et al. 2012). This study showed a significantly decreased in TAS and GSH levels, a significantly higher serum leptin, hs-CRP and MDA between patients with hypertension before treatment in comparison with controls. After 3 months therapy with lisinopril, a significant increase in TAS, GSH and HDL levels, and a significant reduction in serum leptin, MDA and hs-CRP were found in such patients in comparison to pretreatment values. These results were in agreement with results of studies which reported that patients with essential hypertension observe a significantly lower antioxidant markers as compared with healthy subjects and that TAS values increased during therapy with antihypertensive drug (Merkhan et al. 2020). The conclusion drawn from the presence of oxidative stress, diminished Total antioxidant status and elevated superoxide dismutases with a decreased levels of glutathione as well as the finding of hypertension, which was substantiated, was that inflammation (as evidenced by an increase in MDA and decrease in SOD) and the increase in hsCRP indicated that hypertension is usually associated with an inflammatory response (Erejuwa et al. 2011; Hage 2014).

Recent research has established that oxidative stress plays a significant role in the development of hypertension (Merkhan et al. 2021). Oxidative stress has gained prominence as a critical mechanism underlying the development of hypertension. Reactive oxygen species (ROS) play a critical role in maintaining the vascular wall’s homeostasis; thus, they may be a component of the mechanism underlying hypertension (Sies and Jones 2020; Abdullah et al. 2021). Thus, in experimental and human hypertension, increased reactive oxygen species (ROS) production, decreased nitric oxide (NO) levels, and decreased antioxidant bioavailability were observed (Ray et al. 2012). When stimulated by hormones such as angiotensin II (AT-II), endothelin-1 (ET-1), and urotensin II, vascular superoxide dismutase is primarily derived from nicotinamide adenine dinucleotide diphosphate (NADPH) oxidase (Hend et al. 2021). It has also been proven that mechanical stimuli cause an increase in the formation of free radicals, which lead to an additional increase in the circulating R’(+O) S levels in those who have hypertension. Increased intracellular calcium concentrations has a deleterious effect on the formation of vasoconstriction, which in itself is thought to contribute to hypertension (Andreadou et al. 2020). The amount of the vascular elements and oxygen demand are adjusted by the presence of oxidative stress, each of which is made to maintain a precise balance by the interactions of the vasodilator and vasoconstrictor forces, both of which are determined by the quantity of red blood cells. These studies have piqued interest in medications that inhibit free radical formation or delivery to tissues and are now being investigated a new classes of antihypertensive agents (Andreadou et al. 2020).

This study also showed that the hs-CRP levels in patients with hypertension were significantly higher than those of healthy controls and that the administration of the antihypertensive drug, lisinopril, for 3 months was associated with a significant reduction in its level. Many studies reported that hsCRP is significantly elevated in patients with essential hypertension, normalizing over weeks on therapy, thereby correlating with clinical response (Almukhtar et al. 2020; Caetano-Silva et al. 2021). C-reactive protein (CRP) is a marker of systemic inflammation that has been linked to an increased risk of hypertension development. Although numerous studies demonstrate that elevated circulating CRP levels are associated with elevated blood pressure, these associations may be noncausal. Numerous clinical findings corroborate the existence of a link between interleukin-6, IL-6, and CRP (Volpe 2008).

### Table 4. Correlations between blood pressure and leptin in all studied groups.

| Parameter | Systolic blood pressure | Diastolic blood pressure |
|-----------|-------------------------|-------------------------|
|           | r  | p-value | r  | p-value |
| Leptin (ng/ml) | 0.8 | 0.01 | 0.7 | 0.01 |
studies have found increased plasma leptin levels in hypertensive patients (Nagamia et al. 2007). Moreover, leptin plays a role in end organ damage related to hypertension, including left ventricular hypertrophy, retinopathy, and nephropathy (Al-Thanoon and Mahmood 2012; Nedogoda et al. 2013). The role of leptin in blood pressure regulation and arterial hypertension is illustrated in various studies (Furuhashi et al. 2003; Althanoon et al. 2020). Correlation analysis the results of the present study found that there was a positive correlation between leptin and hsCRP, MDA, TC, TG and LDL-C, as shown in Table 3, and there was a negative correlation between leptin and TAS, GSH and HDL, a significant positive correlation was found between systolic and diastolic blood pressure and leptin in all studied groups (Table 4), these findings were in agreement with other studies as reported by Man et al. 2020; Ahmad et al. 2019. Interestingly, in the current study, hypertensive patients treated with lisinopril result in a significant improvement in leptin, hsCRP, MDA, TC, TG, and LDL-C levels, despite the fact that they did not change their diet in any way during the course of the study. To date, it has not been determined whether such an effect was a cause or a result of the observed changes in leptin levels and insulin resistance.

**Conclusion**

The findings of this study suggest that, while the ACEI lisinopril has effective blood pressure lowering effects, lisinopril may have an advantage in the treatment of hypertensive subjects because of its improvement of some obesity-related metabolic disorders, such as BMI, hyperleptinemia, and insulin resistance, as well as its lack of sympathetic activation. As a result, lisinopril may be used as a medication for patients with hypertension to lower their blood pressure while also improving their insulin resistance, hyperleptinemic status, and low-grade inflammatory condition.

**Acknowledgements**

We thank the regional research ethics committees at the University of Mosul, College of Pharmacy and Health Administration Research Technical Support for their Ethics approval of the study. We are grateful to all of the medical staff of out-patient clinic in IBN-SINA Teaching Hospital in Mosul city for their support in carrying out the requirement of the research study.

Financial support and sponsorship: The research was fully self-funded.

**Conflicts of interest**

No potential conflicts exist. We had full access to all the information in the study and take full responsibility for the integrity of the information and the accuracy of the data analysis.

**References**

Abdollahi A, Shoar S, Nayyeri F, Shariat M (2012) Diagnostic value of simultaneous measurement of procalcitonin, interleukin-6 and hs-CRP in prediction of early-onset neonatal sepsis. Mediterranean Journal of Hematology and Infectious Diseases 4(1): e2012028. https://doi.org/10.4084/mjhid.2012.028

Abdullah E, Dhlia S, Saleh K, Merkhan M (2021) Effect of esomeprazole on lipid profile in patients with peptic ulcer. Bangladesh Renal Journal 68(3): 613–617. https://doi.org/10.3897/pharmacia.68.e70292

Abdulrazzaq G, Khalaf MM, Merkhan MM (2020) Allopurinol therapy impairs lipid metabolism in patients with renal stone. Current Topics in Pharmacology 24: 105–112.

Ahmad AA, Almukhtar HM, Merkhan MM (no date) Vasomotor impact of perivascular adipose tissue on coronary circulation. 11 pp.

Ahmad AA, Merkhan MM, Abdulrazzaq GM (2021) Effect of xanthine oxidase inhibition on immunity modulation in human. European Journal of Molecular & Clinical Medicine 7(10): 1307–1316.

Al-Hamodi Z, Al-Meeri A, Saif-Ali R (2014) Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetology and Metabolic Syndrome 6(1): 4–11. https://doi.org/10.1186/1758-5966-6-99

Al-Thanoon ZA, Mahmood MH (2012) Effects of losartan vs. enalapril on the markers of metabolic syndrome. Oman Medical Journal 27(1): 27–30. https://doi.org/10.5001/omj.2012.05

Almukhtar HM, Faisal IM, Merkhan MM (2020) Effects of statins on platelet count in hyperlipidemic patients. International Journal of Pharmaceutical Research 12(2): 2640–2644. https://doi.org/10.31838/ijpr/2020.12.02.357

Almukhtar HM, Faisal IM, Merkhan MM (2021) Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients. Pharmacology 25: 25–34.

Althanoon Z, Faisal IM, Ahmad AA, Merkhan MM (2020) Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Systematic Reviews in Pharmacy 11(7): 167–171. http://dx.doi.org/10.31838/srp.2020.7.27

Ames MK, Atkins CE, Pitt B (2019) The renin-angiotensin-aldosterone system and its suppression. Journal of Veterinary Internal Medicine 33(2): 363–382. https://doi.org/10.1111/jvim.15454

Andreadou I, Schulz R, Papapetropoulos A, Turan B, Ytrehus K, Ferdinandy P, Daiber A, Di Lisa F (2020) The role of mitochondrial reactive oxygen species, NO and H2S in ischaemia/reperfusion injury and cardioprotection. Journal of Cellular and Molecular Medicine 24(12): 6510–6522. https://doi.org/10.1111/jcmm.15279

Arif M, Sadayappan S, Becker RC, Martin LJ, Urbina EM (2019) Epigenetic modification: a regulatory mechanism in essential hypertension. Hypertension Research 42(8): 1099–1113. https://doi.org/10.1080/11789728.2019.1645581

Balakumar P, Sambathkumar R, Mahadevan N, Bin Muhsinah A, Alsary A, Venkateswaranurthy N, Jagadeesh G (2019) A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: Mechanisms and
Romero JC, Reckelhoff JF (1999) Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34(4 II): 943–949. https://doi.org/10.1161/01.HYP.34.4.943

Serafi AS, Bafail MA, Hussain Z (2016) Role of leptin in hypertension: a short review. International Journal of Biology and Biotechnology 13(3): 453–458.

Shankar A, Xiao J (2010) Positive relationship between plasma leptin level and hypertension. Hypertension 56(4): 623–628. https://doi.org/10.1161/HYPERTENSIONAHA.109.148213

Sies H, Jones DP (2020) Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nature Reviews Molecular Cell Biology 21(7): 363–383. https://doi.org/10.1038/s41580-020-0230-3

Volpe M (2008) Microalbuminuria screening in patients with hypertension: Recommendations for clinical practice. International Journal of Clinical Practice 62(1): 97–108. https://doi.org/10.1111/j.1742-1241.2007.01620.x

Von Schnurbein J, Manzoor J, Brandt S, Denzer F, Kohlsdorf K, Fischer-Posovszky P, Weißenberger M, Frank-Podlech S, Mahmoud S, Wabitsch M (2019) Leptin is not essential for obesity-associated hypertension. Obesity Facts 12(4): 460–475. https://doi.org/10.1159/000501319

Xie D, Bollag WB (2016) Obesity, hypertension and aldosterone: Is leptin the link? Journal of Endocrinology 230(1): F7–F11. https://doi.org/10.1530/JOE-16-0160

Younis HY, Thanoon IA, Fadhil NN, Merkhan MM (2021) Effect of zinc as an add on to metformin therapy on serum lipid profile and uric acid in type 2 diabetes mellitus patients. Current Topics in Pharmacology 25: 53–59.